| A strategic approach to COVID-19 vaccine R&D #MMPMID32393526Corey L; Mascola JR; Fauci AS; Collins FSScience 2020[May]; 368 (6494): 948-950 PMID32393526show ga
ä|*Public-Private Sector Partnerships[MESH]|*Viral Vaccines/adverse effects/immunology[MESH]|Adjuvants, Immunologic[MESH]|Animals[MESH]|Betacoronavirus/*immunology[MESH]|COVID-19[MESH]|COVID-19 Vaccines[MESH]|Clinical Trial Protocols as Topic[MESH]|Clinical Trials as Topic[MESH]|Coronavirus Infections/immunology/*prevention & control[MESH]|Disease Models, Animal[MESH]|Humans[MESH]|Immunogenicity, Vaccine[MESH]|International Cooperation[MESH]|National Institutes of Health (U.S.)[MESH]|Pandemics/*prevention & control[MESH]|Pneumonia, Viral/immunology/*prevention & control[MESH]|RNA, Messenger[MESH]|SARS-CoV-2[MESH]|Spike Glycoprotein, Coronavirus/immunology[MESH]|T-Lymphocytes/immunology[MESH]|United States[MESH]|Vaccines, DNA[MESH]
DeepDyve Pubget Overpricing |
|